US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
pharma · Bleeding Complication During Colon Polypectomy · Cancer of Colon
Yang Xiaotian
Yang Xiaotian drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 5
- Drugs
- 2
- Patents
- 0
Yang Xiaotian pipeline
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Yang Xiaotian drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent